Stage: Preclinical development
Area: Cell therapy
Status: Ongoing
Patent: Main patent secured and licenced, more patents filed and in progress
Atherosclerosis is the main cause of cardiovascular disease (CVD), an age-related disease ranking as the number 1 killer in the world, responsible for a quarter of all deaths according to recent World Health Organization data. In atherosclerosis, plaques that are mainly made up of cholesterol build up over time in the walls of arteries, restricting or even blocking the flow of oxygen-rich blood to organs and other parts of the body. In arteries, cholesterol is carried by low-density lipoproteins or LDLs. In young individuals, macrophages help clear excess LDL cholesterol from artery walls but with aging, they become overwhelmed and ineffective.
To date, no therapy can reduce plaque size. Current medical treatments for atherosclerosis, like statins, which are inhibitors of cholesterol production, can only slow its accumulation in plaques. Statins do reduce cardiovascular events by about 25%, which is already a huge achievement, but do not cure atherosclerosis.
Repair Bio aims to solve macrophage dysfunction with their “Cholesterol-Degrading Platform” (CDP), a novel allogeneic cell therapy. Concretely, the idea is to produce macrophage cells engineered to have better LDL disposal capabilities and deliver them to patients.
Repair manufactures these enhanced macrophages in a series of steps (see figure below):
In-vitro tests of these enhanced macrophages have shown that they can break down excess ingested cholesterol into safe catabolites. Encouraging results were also obtained in vivo in a strain of mice used for studying cardiovascular disease: in this proof of concept (POC) study, mice on a high-fat diet were treated with a gene therapy implementation of Repair’s approach. The treated mice exhibited a rapid halving of atherosclerotic plaque lipids, an outcome needing only a one-month period following a single treatment, with no identified side effects.
Required Funding: $50,000 (more required but that’s what we’re providing)
Status: Ongoing
Repair Bio is targeting the deadliest aging-related diseases and a multi-billion dollar market. They have encouraging results of human in-vitro and mice in-vivo proofs of concept as well as comprehensive and recent intellectual property protection. The effort is lead by a solid team with drug development and clinical trial knowledge. There were some risks considered such as early stage approval of iPSC-based therapy, potential side effects of allogeneic cell therapy, and complex manufacturing process.
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
Senescent cells accumulate with age and are associated with numerous diseases. Dr. Amit Sharma’s team have identified senescence-specific cell surface biomarkers which will act as targets for developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells aiming to precisely and safely eliminate senescent cells in vivo.
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.